Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CHTP Stopped out at 2.50 today, 23% beating to add to the other wack I recently took on it a while ago. Luckily I don't invest much in a given stock. Oh well can't win em all. Twice burned is enough/
Big C they may well do what you say I just think it is early yet to be doing it, who knows anyone's guess
AEZS <link back> it is bouncing back a bit after the offering and yesterdays slide. Happy about buying in on that drop since it should recover ok with the upcoming catalysts Aug ph2 and Nov 5 PDUFA.
AEZS <link back> it is bouncing back a bit after the offering and yesterdays slide. Happy about buying in on that drop since it should recover ok with the upcoming catalysts Aug ph2 and Nov 5 PDUFA.
MNKD Read this article MFs reason for today's drop is sell on the news after a leak yesterday of today's news coming.
http://www.fool.com/investing/general/2014/01/10/intercept-pharmaceuticals-and-mannkind-could-be-bi.aspx
Bigc that manipulation could be at times, however this float is 20% short, and when they see the volume top or slow to rest and wain after a 20% day they swoop in. Imo there is little need to sell when the news is good like today.
I sold yesterday 31% gain and bought back in today at 6.06 a bunch.
I think it is posturing being done by shorts after a big days run on a heavily shorted stock. Could be wrong so I have bracket stops in. If they do an offering shorts will pile on and drop it more, not sure they need to yet though. Go to Finviz look at COH cash/shr x O/S
jmho
MNKDThe float is 20% short, but they will cover imho or many of them now and their chances are thinning. Today was a huge opportunity thus far. jmho
MNKD Exited T/Stop with 31% gain @7.03 on all but 1/6 of the shares which now I am holding. Good trade, but the TS was too tight. I think it should have a fair bit of room to flip between now and PDUFA. The little I have left won't account for much one way or the other but it will keep me watching it at least.
MNKD Exited T/S with 31% gain @7.03 on all but 1/6 of the shares which now I am holding. Good trade, but I think it should have a fair bit of room to flip between now and PDUFA. The little I have left won't account for much one way or the other but it will keep me watching it at least.
MNKD Typo on chart should say 1/9 notes NOT 8/9
MNKD<link back> This one is starting to move and a 4/15 PDUFA lots of time to run. Up 12% or so for the day, been creeping a just a few % a day for a bit now.
Sheff after getting stopped out at 3.29 or some such the other day; yesterday I finally decided to get back in on its bounce back up and reentered at 3.25, you seemed to have some fairly solid faith in it, so I took the leap.
Today it is doing well, up 8% and recovered all but .03 of my original cost on the other bunch which I got stopped out on. Now I feel comfortable even though it is very, very light pink it looks like green is around the corner, just .03 away.lol
Thanks for the info and the conviction you had on it.
T2M
Senderos as a holder of it I couldn't agree more.
ATHX 35% gain Trailing Stop put me out. Will look at reentering.
ATHX T/S exit 35% gain - out for now but may reenter.
IGXT CEO just options - none the less could bode well for upcoming PDUFA
" New CEO took over on Jan. 1, and he filed a Form 4 about 30 minutes ago. "
SF TY for that, never used the "Jan Effect" still learn something new every day.
You surely called it and it is doing very well for you, KUDOS
T2M
SF PGRX what is the event causing this? I sold wayyy early grr
made a nice profit but left a huge amount on the table.
TIA
T2M
MNKD Has nice room to grow with a 4/31 PDUFA, I am hanging on with it out that far, still should have vg upside imho
AEZS In at 1.15 today 21+% off due to stock offering with ADCOM/PDUFA due later this year
CRDC <link back to Alert!> Exited this morning 44.9% gain
Thanks Read This NOW!!!!!!! I owe ya a steak!
CRDC 44.9%gain PM <link back to yesterdays chart> Sold PM today 44.9% gain
BOL nice day to start!
ATHX NEWs it is up 9% today PM
ATHX<link back> MORE Bullish New Today:
1. CEO to interview at Clear Channel 3PM EST today 2PM CST Live Interview
2. Japan - Several Patents now just issued for Cell Therapy
3. Japan - Patents Stem Cell and Regeneration Med Technology
Source Schwab - can not cut and paste not allowed. It will be carried later by other services.
BOL
T2M should be another good day for ATHX! jmho
ATHX<link back> MORE Bullish New Today:
1. CEO to interview at Clear Channel 3PM EST today 2PM CST Live Interview
2. Japan - Several Patents now just issued for Cell Therapy
3. Japan - Patents Stem Cell and Regeneration Med Technology
Source Schwab - can not cut and paste not allowed. It will be carried later by other services.
BOL
T2M should be another good day for ATHX! jmho
PRGX thanks for that heads up Stockfather, made me 27% left some on the table, but wanted to ensure the table would always have 4 legs.
TYVM
T2M
Patagonia Those APPY form 4s are not open market buys, unlike last Friday with MSTX. jmho
CRDC ALERT <annotated Chart> Read This Now gave the heads up. He also posted about an AUG 510K which is due any day from the FDA. At least one other tonight came out for a bio so perhaps this one will by tomorrow. Something is happening now since AH the stock is up 9% on no news!!! Thanks Read This now! 510 was great info.
SQNM <link back> Patent announcement
Sequenom Announces Issuance Of European Patent For Novel Methods Of Detecting Fetal Aneuploidy
Date : 01/08/2014 @ 5:24PM
Source : PR Newswire (US)
Stock : Sequenom, Inc. (MM) (SQNM)
Quote : 2.46 0.03 (1.23%) @ 5:38PM
Sequenom Announces Issuance Of European Patent For Novel Methods Of Detecting Fetal Aneuploidy
Print
Alert
Sequenom, Inc. (MM) (NASDAQ:SQNM)
Intraday Stock Chart
Today : Wednesday 8 January 2014
Click Here for more Sequenom, Inc. (MM) Charts.
SAN DIEGO, Jan. 8, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative testing and genetic analysis solutions, today announced that on January 1, 2014, the European Patent Office (EPO) issued patent EP2183693 B1, entitled "Diagnosing Fetal Chromosomal Aneuploidy Using Genomic Sequencing," invented by Drs. Dennis Lo, Rossa Chiu, and Kwan Chee Chan of The Chinese University of Hong Kong. The patent claims novel methods for detecting fetal aneuploidy using sequencing and was the first patent filing made in the EPO directed to such novel methods. Sequenom holds exclusive rights to the patent, an important part of Sequenom's prenatal diagnostic patent portfolio, with coverage across all countries in the European Union, and also including Liechtenstein, Monaco, Norway and Switzerland.
About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genomic and genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostic markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.
Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Sequenom's commitment to improving healthcare through revolutionary genetic analysis solutions, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with Sequenom's ability to develop and commercialize new technologies and products, particularly new technologies such as prenatal and other diagnostics and laboratory developed tests, Sequenom's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, ongoing litigation including patent litigation, and other risks detailed from time to time in Sequenom's most recent Quarterly and Annual Reports on Securities and Exchange Commission Forms 10-Q and 10-K, respectively, and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.